Relationship of type 1 cannabinoid receptor availability in the human brain to novelty-seeking temperament

Archives of General Psychiatry

Volumn 66, Issue 2, 2009, Pages 196-204

  Van Laere, Koen ^a,c   Goffin, Karolien ^a   Bormans, Guy ^b   Casteels, Cindy ^a   Mortelmans, Luc ^a   De Hoon, Jan ^c   Grachev, Igor ^b   Vandenbulcke, Mathieu ^a   Pieters, Guido ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b MERCK RESEARCH LABORATORIES   (United States)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CANNABINOID 1 RECEPTOR;

ADULT; AMYGDALOID NUCLEUS; ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN EXPERIMENT; NEUROIMAGING; NEUROTRANSMISSION; NORMAL HUMAN; OUTCOME ASSESSMENT; POSITRON EMISSION TOMOGRAPHY; TEMPERAMENT;

ADOLESCENT; ADULT; AGED; AMYGDALA; BRAIN; BRAIN MAPPING; DOMINANCE, CEREBRAL; EXPLORATORY BEHAVIOR; FEMALE; FLUORINE RADIOISOTOPES; GYRUS CINGULI; HUMANS; MALE; MIDDLE AGED; PARIETAL LOBE; PERSONALITY INVENTORY; POSITRON-EMISSION TOMOGRAPHY; PYRIDINES; RECEPTOR, CANNABINOID, CB1; REFERENCE VALUES; STATISTICS AS TOPIC; TEMPERAMENT; YOUNG ADULT;

EID: 59649114383     PISSN: 0003990X     EISSN: 15383636     Source Type: Journal    
DOI: 10.1001/archgenpsychiatry.2008.530     Document Type: Article

References (50)

1. Farde L, Gustavsson JP, Jönsson E. D2 dopamine receptors and personality traits. Nature. 1997;385(6617):590.
2. Cloninger CR, Svrakic DM, Przybeck TR. A psychobiological model of temperament and character. Arch Gen Psychiatry. 1993;50(12):975-990.
3. Miettunen J, Lauronen E, Kantojarvi L, Veijola J, Joukamaa M. Inter-correlations between Cloninger's temperament dimensions: a meta-analysis. Psychiatry Res. 2008; 160(1):106-114.
4. Cloninger CR. A systematic method for clinical description and classification of personality variants: a proposal. Arch Gen Psychiatry. 1987;44(6):573-588.
5. Heath AC, Cloninger CR, Martin NG. Testing a model for the genetic structure of personality: a comparison of the personality systems of Cloninger and Eysenck. J Pers Soc Psychol. 1994;66(4):762-775.
6. 2A receptor binding and personality traits in healthy subjects: a positron emission tomography study. Neuroimage. 2002;17(3):1470-1478.
7. Kaasinen V, Nurmi E, Bergman J, Eskola O, Solin O, Sonninen P, Rinne JO. Personality traits and brain dopaminergic function in Parkinson's disease. Proc Natl Acad Sci U S A. 2001;98(23):13272-13277.
8. 2 receptor binding, obesity and personality in normal human subjects. Neurosci Lett. 2001;300(1):59-61.
9. Di Marzo V, Bifulco M, De Petrocellis L. The endocannabinoid system and its therapeutic exploitation. Nat Rev Drug Discov. 2004;3(9):771-784.
10. Wilson RI, Nicoll RA. Endocannabinoid signaling in the brain. Science. 2002;296(5568):678-682.
11. Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rossner S. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet. 2005;365(9468):1389-1397.
12. Després JP, Golay A, Sjöström L; Rimonabant in Obesity-Lipids Study Group. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med. 2005;353(20):2121- 2134.
13. Addy C, Wright H, Van Laere K, Gantz I, Erondu N, Musser BJ, Lu K, Yuan J, Sanabria-Bohorquez S, Stoch A, Stevens C, Fong TM, De Lepeleire I, Cilissen C, Cote J, Rosko K, Gendrano IN III, Nguyen AM, Gumbiner B, Rothenberg P, de Hoon J, Bormans G, Depre M, Eng WS, Ravussin E, Klein S, Blundell J, Herman GA, Burns HD, Hargreaves R, Wagner JA, Gottesdiener K, Amatruda JM, Heymsfield SB. The acyclic CB1R inverse agonist taranabant mediates weight loss by increasing energy expenditure and decreasing caloric intake. Cell Metab. 2008;7(1):68-78.
14. Maldonado R, Valverde O, Berrendero F. Involvement of the endocannabinoid system in drug addiction. Trends Neurosci. 2006;29(4):225-232.
15. Solinas M, Yasar S, Goldberg SR. Endocannabinoid system involvement in brain reward processes related to drug abuse. Pharmacol Res. 2007;56(5):393-405.
16. 18F]MK-9470, a positron emission tomography (PET) tracer for in vivo human PET brain imaging of the cannabinoid-1 receptor. Proc Natl Acad Sci USA. 2007;104(23):9800-9805.
17. 18F]MK-9470 PET. Neuroimage. 2008;39(4):1533-1541.
18. Borg J, Andrée B, Soderstrom H, Farde L. The serotonin system and spiritual experiences. Am J Psychiatry. 2003;160(11):1965-1969.
19. Briggs GG, Nebes RD. Patterns of hand preference in a student population. Cortex. 1975;11(3):230-238.
20. Maldjian JA, Laurienti PJ, Kraft RA, Burdette JH. An automated method for neuroanatomic and cytoarchitectonic atlas-based interrogation of fMRI data sets. Neuroimage. 2003;19(3):1233-1239.
21. Friston KJ, Frith CD, Liddle PF, Frackowiak RS. Comparing functional (PET) images: the assessment of significant change. J Cereb Blood Flow Metab. 1991;11(4):690-699.
22. Ebstein RP. The molecular genetic architecture of human personality: beyond self-report questionnaires. Mol Psychiatry. 2006;11(5):427-445.
23. Cloninger CR. Functional neuroanatomy and brain imaging of personality and its disorders. In: D'haenen H, den Boer JA, Willner P, eds. Biological Psychiatry. Chichester, England: John Wiley & Sons; 2002:1377-1386.
24. Machado CJ, Bachevalier J. The impact of selective amygdala, orbital frontal cortex, orhippocampal formation lesions on established social relationships in rhesus monkeys (Macaca mulatta). Behav Neurosci. 2006;120(4):761-786.
25. Kamprath K, Marsicano G, Tang J, Monory K, Bisogno T, Di Marzo V, Lutz B, Wotjak CT. Cannabinoid CB1 receptor mediates fear extinction via habituation-like processes. J Neurosci. 2006;26(25):6677-6686.
26. Marsicano G, Wotjak CT, Azad SC, Bisogno T, Rammes G, Cascio MG, Hermann H, Tang J, Hofmann C, Zieglgansberger W, Di Marzo V, Lutz B. The endogenous cannabinoid system controls extinction of aversive memories. Nature. 2002;418(6897):530-534.
27. Laviolette SR, Grace AA. The roles of cannabinoid and dopamine receptor systems in neural emotional learning circuits: implications for schizophrenia and addiction. Cell Mol Life Sci. 2006;63(14):1597-1613.
28. Davidson RJ. Affective style, psychopathology, and resilience: brain mechanisms and plasticity. Am Psychol. 2000;55(11):1196-1214.
29. Puttonen S, Ravaja N, Keltikangas-Jarvinen L. Cloninger's temperament dimensions and affective responses to different challenges. Compr Psychiatry. 2005;46(2):128-134.
30. Terry G, Liow JS, Chernet E, Zoghbi SS, Phebus L, Felder CC, Tauscher J, Schaus JM, Pike VW, Halldin C, Innis RB. Positron emission tomography imaging using an inverse agonist radioligand to assess cannabinoid CB1 receptors in rodents. Neuroimage. 2008;41(3):690-698.
31. Griebel G, Stemmelin J, Scatton B. Effects of the cannabinoid CB1 receptor antagonist rimonabant in models of emotional reactivity in rodents. Biol Psychiatry. 2005;57(3):261-267.
32. Hiroi N, Agatsuma S. Genetic susceptibility to substance dependence. Mol Psychiatry. 2005;10(4):336-344.
33. Hutchison KE, Haughey H, Niculescu M, Schacht J, Kaiser A, Stitzel J, Horton WJ, Filbey F. The incentive salience of alcohol: translating the effects of genetic variant in CNR1. Arch Gen Psychiatry. 2008;65(7):841-850.
34. Fattore L, Deiana S, Spano SM, Cossu G, Fadda P, Scherma M, Fratta W. Endocannabinoid system and opioid addiction: behavioural aspects. Pharmacol Biochem Behav. 2005;81(2):343-359.
35. Beardsley PM, Thomas BF. Current evidence supporting a role of cannabinoid CB1 receptor (CB1R) antagonists as potential pharmacotherapies for drug abuse disorders. Behav Pharmacol. 2005;16(5-6):275-296.
36. O'Gorman RL, Kumari V, Williams SC, Zelaya FO, Connor SE, Alsop DC, Gray JA. Personality factors correlate with regional cerebral perfusion. Neuroimage. 2006;31(2):489-495.
37. 1A receptors in normal male volunteers: normative data and relationship to methodological, demographic, physiological, and behavioral variables. Neuroimage. 2002;15(3):620-632.
38. 11C]raclopride/ positron emission tomography study in healthy men. Arch Gen Psychiatry. 2006;63(12):1386-1395.
39. Breier A, Kestler L, Adler C, Elman I, Wiesenfeld N, Malhotra A, Pickar D. Dopamine D2 receptor density and personal detachment in healthy subjects. Am J Psychiatry. 1998;155(10):1440-1442.
40. Laakso A, Vilkman H, Kajander J, Bergman J, Paranta M, Solin O, Hietala J. Prediction of detached personality in healthy subjects by low dopamine transporter binding. Am J Psychiatry. 2000;157(2):290-292.
41. Laine TP, Ahonen A, Rasanen P, Tiihonen J. Dopamine transporter density and novelty seeking among alcoholics. J Addict Dis. 2001;20(4):91-96.
42. Compton PA, Anglin MD, Khalsa-Denison ME, Paredes A. The D2 dopamine receptor gene, addiction, and personality: clinical correlates in cocaine abusers. Biol Psychiatry. 1996;39(4):302-304.
43. 18F]dopa striatal uptake: results of positron-emission tomography in Parkinson's disease. J Neuropsychiatry Clin Neurosci. 1995;7(2):176-179.
44. van der Stelt M, Di Marzo V. The endocannabinoid system in the basal ganglia and in the mesolimbic reward system: implications for neurological and psychiatric disorders. Eur J Pharmacol. 2003;480(1-3):133-150.
45. Malone DT, Taylor DA. Modulation by fluoxetine of striatal dopamine release following Δ9-tetrahydrocannabinol: a microdialysis study in conscious rats. Br J Pharmacol. 1999;128(1):21-26.
46. 1) receptor antagonist, blocks the motivational and dopamine- releasing effects of nicotine in rats. Behav Pharmacol. 2002;13(5-6):451-463.
47. Köfalvi A, Rodrigues RJ, Ledent C, Mackie K, Vizi ES, Cunha RA, Sperlagh B. Involvement of cannabinoid receptors in the regulation of neurotransmitter release in the rodent striatum: a combined immunochemical and pharmacological analysis. J Neurosci. 2005;25(11):2874-2884.
48. Trettel J, Levine ES. Endocannabinoids mediate rapid retrograde signaling atinterneuron right-arrow pyramidal neuron synapses of the neocortex. J Neurophysiol. 2003;89(4):2334-2338.
49. Piomelli D. The molecular logic of endocannabinoid signalling. Nat Rev Neurosci. 2003;4(11):873-884.
50. Julian MD, Martin AB, Cuellar B, Rodriguez DF, Navarro M, Moratalla R, Garcia- Segura LM. Neuroanatomical relationship between type 1 cannabinoid receptors and dopaminergic systems in the rat basal ganglia. Neuroscience. 2003;119(1):309-318.